These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 24458094)
1. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Zhang W; Gao Y; Li P; Shi Z; Guo T; Li F; Han X; Feng Y; Zheng C; Wang Z; Li F; Chen H; Zhou Z; Zhang L; Ji H Cell Res; 2014 Mar; 24(3):331-43. PubMed ID: 24458094 [TBL] [Abstract][Full Text] [Related]
2. VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs. Deng X; Fang L Am J Cancer Res; 2018; 8(6):932-943. PubMed ID: 30034932 [TBL] [Abstract][Full Text] [Related]
3. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. Jiao S; Li C; Hao Q; Miao H; Zhang L; Li L; Zhou Z Nat Commun; 2017 Jan; 8():14058. PubMed ID: 28051067 [TBL] [Abstract][Full Text] [Related]
4. YAP-VGLL4 antagonism defines the major physiological function of the Hippo signaling effector YAP. Cai J; Choi K; Li H; Pulgar Prieto KD; Zheng Y; Pan D Genes Dev; 2022 Nov-Dec 1; 36(21-24):1119-1128. PubMed ID: 36522128 [TBL] [Abstract][Full Text] [Related]
5. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Lin Z; Guo H; Cao Y; Zohrabian S; Zhou P; Ma Q; VanDusen N; Guo Y; Zhang J; Stevens SM; Liang F; Quan Q; van Gorp PR; Li A; Dos Remedios C; He A; Bezzerides VJ; Pu WT Dev Cell; 2016 Nov; 39(4):466-479. PubMed ID: 27720608 [TBL] [Abstract][Full Text] [Related]
6. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Jiao S; Wang H; Shi Z; Dong A; Zhang W; Song X; He F; Wang Y; Zhang Z; Wang W; Wang X; Guo T; Li P; Zhao Y; Ji H; Zhang L; Zhou Z Cancer Cell; 2014 Feb; 25(2):166-80. PubMed ID: 24525233 [TBL] [Abstract][Full Text] [Related]
7. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor. Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450 [TBL] [Abstract][Full Text] [Related]
8. VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Zhang Y; Shen H; Withers HG; Yang N; Denson KE; Mussell AL; Truskinovsky A; Fan Q; Gelman IH; Frangou C; Zhang J Sci Rep; 2017 Jul; 7(1):6190. PubMed ID: 28733631 [TBL] [Abstract][Full Text] [Related]
9. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Chan P; Han X; Zheng B; DeRan M; Yu J; Jarugumilli GK; Deng H; Pan D; Luo X; Wu X Nat Chem Biol; 2016 Apr; 12(4):282-9. PubMed ID: 26900866 [TBL] [Abstract][Full Text] [Related]
10. Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway. Li X; Liu Y; Zhang C; Niu Q; Wang H; Che C; Xie M; Zhou B; Xu Y; Zhang Q; Wu J; Tian Z Oncotarget; 2017 Mar; 8(10):16356-16366. PubMed ID: 28099921 [TBL] [Abstract][Full Text] [Related]
12. Activation of VGLL4 Suppresses Cardiomyocyte Maturational Hypertrophic Growth. Farley A; Gao Y; Sun Y; Zohrabian S; Pu WT; Lin Z Cells; 2024 Aug; 13(16):. PubMed ID: 39195232 [TBL] [Abstract][Full Text] [Related]
13. VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype. Mickle M; Adhikary G; Shrestha S; Xu W; Eckert RL Mol Carcinog; 2021 Jul; 60(7):497-507. PubMed ID: 34004031 [TBL] [Abstract][Full Text] [Related]
14. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Zhao B; Kim J; Ye X; Lai ZC; Guan KL Cancer Res; 2009 Feb; 69(3):1089-98. PubMed ID: 19141641 [TBL] [Abstract][Full Text] [Related]
15. S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells. Wang R; Li Y; Hu E; Kong F; Wang J; Liu J; Shao Q; Hao Y; He D; Xiao X Oncotarget; 2017 Apr; 8(15):24804-24814. PubMed ID: 28177901 [TBL] [Abstract][Full Text] [Related]
16. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer. Kim JY; Kim EK; Lee WM; Hong YO; Lee H APMIS; 2020 Oct; 128(10):543-551. PubMed ID: 32794608 [TBL] [Abstract][Full Text] [Related]
17. Vestigial like 4 regulates the adipogenesis of classical brown adipose tissue. Zhou P; Kessinger CW; Gu F; Davenport A; King JS; Wang G; Negron SG; Deplancke B; Pu WT; Lin Z bioRxiv; 2024 Jul; ():. PubMed ID: 39026854 [TBL] [Abstract][Full Text] [Related]
18. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion. Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996 [TBL] [Abstract][Full Text] [Related]
19. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750 [TBL] [Abstract][Full Text] [Related]
20. VGLL4 promotes osteoblast differentiation by antagonizing TEADs-inhibited Runx2 transcription. Suo J; Feng X; Li J; Wang J; Wang Z; Zhang L; Zou W Sci Adv; 2020 Oct; 6(43):. PubMed ID: 33097532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]